CHECKMATE-032
Regimen
- Experimental
- nivolumab monotherapy or nivolumab + ipilimumab (various doses)
- Control
- no control (single-arm cohorts)
Population
Recurrent/progressive small-cell lung cancer after prior chemotherapy
Key finding
ORR: nivo3 10% (10/98); nivo1+ipi3 23% (14/61); nivo3+ipi1 19% (10/54); durable responses observed
Source: PMID 27269741
Timeline
Guideline citations
- NCCN SCLC (p.26)
- CSCO SCLC 2025 (p.34)⚠️ OCR source